Denca designs control system for pharma facility

Published: 3-Mar-2011
Manufacturing Finance Pharmaceutical

Project in Liverpool worth £500,000

UK-based automation and control systems specialist Denca Controls has been commissioned by a UK producer of pharmaceuticals and biotechnology to supply control systems for its new manufacturing facility in Liverpool in a project worth £500,000.

The new plant is being built to meet demand for the pharmaceutical firm’s dialysis substitute, which frees patients from the need to be connected to a dialysis machine for 8 hours at a time, instead enabling blood to be cleaned from the convenience of a portable bag.

Denca, based in Widnes, Cheshire has used its expertise to develop process diagrams, design and manufacture control panels, as well as provide software, programming, installation and commissioning. In total, five Siemens S7300 PLCs will be networked with MP 277 touchscreen HMIs, a Profibus Remote IO and communication.

John Talbot, sales and marketing director at Denca, said: ‘It’s not often in our line of work that you are given the opportunity to help, in however small a way, to improve lives. In this case, it’s hugely rewarding to know that, through the implementation of control systems for this groundbreaking new product, we would ultimately be helping the company to provide patients with a better control system to make their day to day lives a little easier.’

Denca works across a spectrum of industry sectors including automotive, chemical, food and beverage, healthcare and utilities. It provides process control solutions based on custom-designed, fully integrated PLC and HMI software for both mechanical and electrical operations as well as UKAS-traceable calibration and certification services.

See more

You may also like

Manufacturing

Denca is under control at SAFC plant in Scotland

Read more
Will supply full control system for IPB2 facility at Irvine

Trending Articles

  1. MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
  2. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  3. How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards

Upcoming event

Cleanroom Technology Conference UK

20-21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Denca is under control at SAFC plant in Scotland

Will supply full control system for IPB2 facility at Irvine
Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

FUJIFILM Cellular Dynamics opens new iPSC manufacturing facility in US

The new site will serve as the company's headquarters and will increase Fujifilm's capacity for induced pluripotent stem cell development and manufacturing, as demand increases with new approach methods in research
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

From bespoke to scalable: closing the manufacturing gap in advanced therapeutics

Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Manufacturing

Piramal Pharma Solutions announces partnership with Botanix to support drug substance development

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra
Subscribe now